These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Palacios S Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824 [TBL] [Abstract][Full Text] [Related]
7. Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Chines AA; Komm BS Drugs Today (Barc); 2009 Jul; 45(7):507-20. PubMed ID: 19834628 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene]. Chaki O Clin Calcium; 2007 Jan; 17(1):30-5. PubMed ID: 17211091 [TBL] [Abstract][Full Text] [Related]
9. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Komm BS; Chines AA Maturitas; 2012 Mar; 71(3):221-6. PubMed ID: 22196312 [TBL] [Abstract][Full Text] [Related]
10. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Lewiecki EM Expert Opin Investig Drugs; 2007 Oct; 16(10):1663-72. PubMed ID: 17922629 [TBL] [Abstract][Full Text] [Related]
11. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Genant HK Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498 [TBL] [Abstract][Full Text] [Related]
12. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. de Villiers TJ Climacteric; 2010 Jun; 13(3):210-8. PubMed ID: 20184423 [TBL] [Abstract][Full Text] [Related]
13. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis. Kung AW; Chu EY; Xu L Expert Opin Pharmacother; 2009 Jun; 10(8):1377-85. PubMed ID: 19445558 [TBL] [Abstract][Full Text] [Related]
14. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. Lewiecki EM J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA; Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271 [TBL] [Abstract][Full Text] [Related]
17. Bazedoxifene acetate for the management of postmenopausal osteoporosis. Palacios S Drugs Today (Barc); 2011 Mar; 47(3):187-95. PubMed ID: 21494696 [TBL] [Abstract][Full Text] [Related]
18. Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis. Duggan ST; McKeage K Drugs; 2011 Nov; 71(16):2193-212. PubMed ID: 22035517 [TBL] [Abstract][Full Text] [Related]
19. Use of SERMs for treatment in postmenopausal women. Pinkerton JV; Thomas S J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794 [TBL] [Abstract][Full Text] [Related]
20. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Maximov PY; Lee TM; Jordan VC Curr Clin Pharmacol; 2013 May; 8(2):135-55. PubMed ID: 23062036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]